Indeed, CALR-mutated patients, as first reported by Klampfl and Nangalia [4,5], are younger and characteristically show marked thrombocytosis accompanied by relatively lower hemoglobin and leukocyte counts when compared with JAK2-mutated cases. This evidence concerns the gene JAK2 and thrombocytosis disease.